DICE Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on DICE Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how DICE Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with DICE Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
DICE Therapeutics Inc (DICE Therapeutics), a subsidiary of Eli Lilly and Co is a pre-clinical stage biopharmaceutical company that develops drugs for the treatment of immunological and chronic diseases. The company is investigating its lead product candidate IL-17 (interleukin 17), an immune-cell-derived cytokine to treat psoriasis and other IL-17 mediated chronic immune disorders and other indications. It is also evaluating drug candidates for the treatment of inflammatory bowel disease, fibrosis and other immune-oncology disorders. The company harnesses its proprietary DELSCAPE platform technology to identify selective oral small molecule antagonists to modulate protein-protein interactions (PPI) targets. DICE Therapeutics is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
Suite 300, 400 East Jamie Court, San Francisco, California, 94080
Website
www.dicetherapeutics.com
Telephone
1 650 5661402
No of Employees
71
Industry
Pharmaceuticals and Healthcare
DICE Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| IL-17: |
| Alpha V- Fibrosis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | DICE Therapeutics Inc | Novartis AG | Bristol-Myers Squibb Co | Amgen Inc | Bausch Health Companies Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | Canada |
| City | San Francisco | Basel | Princeton | Thousand Oaks | Laval |
| State/Province | California | Basel-Stadt | New Jersey | California | Quebec |
| No. of Employees | 71 | 75,883 | 34,100 | 28,000 | 20,700 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard Scheller, PhD | Chairman | Executive Board | 2015 | 71 |
| J. Kevin Judice, PhD | Chief Executive Officer | Senior Management | 2013 | 62 |
| John Jacobsen, PhD | Chief Scientific Officer | Senior Management | 2021 | 57 |
| Venkat Thalladi, PhD | Senior Vice President - Chemistry, Manufacturing & Controls | Senior Management | 2021 | - |
| Paul Fatheree | Senior Vice President - Medicinal Chemistry | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer